Phase 1 Study of DISP-10 for Advanced Gastrointestinal Cancers
This study is testing a new combination treatment called DISP-10 for people with advanced gastrointestinal (GI) cancers, including colorectal, gastric, and esophageal adenocarcinoma. DISP-10 combines DV-10 (an adenovirus) with ide-cel (a type of CAR T-cell therapy). To get ide-cel, your own white blood cells will be collected. The main goal of this first phase of the study is to find the safest and most effective dose of DISP-10. Researchers will be looking closely at any side effects and how well participants tolerate the treatment. You may be able to join if you have one of these advanced GI cancers, measurable disease, and a good performance status. The study plans to enroll 66 participants.
- Study design
- This is a Phase 1, open-label study, meaning both you and your doctors will know what treatment you are receiving. It will involve about 66 participants and has two parts: one to find the right dose and another to further test safety and effectiveness.
- What's involved
- Participants will undergo leukapheresis (a procedure to collect blood cells) to create the ide-cel treatment. The study record does not provide details on the number of visits or other specific procedures.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will track treatment-related side effects for up to 90 days, and serious side effects for up to 2 years. The recommended dose will be identified within 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
At a glance
Conditions
NCT07544589
Where you'd take part
This study runs at 5 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
City of Hope
Duarte, Californiano site contact published
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusettsno site contact published
Recruiting
Hoag Memorial Hospital Presbyterian
Newport Beach, Californiano site contact published
Recruiting
Tennessee Oncology
Nashville, Tennesseeno site contact published
Not yet recruiting
University of Cincinnati Cancer Center
Cincinnati, Ohiono site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Treatment Emergent Adverse Events (TEAEs)90 days (2 years for related Serious Adverse Events)
Graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v6.0
- Incidence of Dose Limiting Toxicities (DLTs) [PART 1]28 days
Graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v6.0
- Identification of the Recommended Dose for Expansion (RDE) [PART 1]Up to 2 years
To select the Recommended Dose for Expansion (RDE) for Part 2
- Overall response rate (ORR) [PART 2]Up to 2 years
Confirmed complete response (CR) or partial response (PR), per RECIST v1.1